お知らせ • Apr 03
Sintx Technologies, Inc. Announces Board Changes
SINTX Technologies, Inc. announced changes to its Board of Directors. The updates reflect the Company’s ongoing strategic transformation into a focused medical technology business. Key changes include the retirement of longtime Chairman Dr. B. Sonny Bal, the appointment of President and CEO Eric Olson as Chairman of the Board, and the addition of five new directors with decades of industry expertise spanning orthopedics, spine, interventional pain, cardiovascular, medical device business development and global commercialization. Dr. Bal has served as a Board Member since 2012, as Executive Chairman since 2014, and as President and CEO from 2015 to 2024. During his tenure, he helped establish SINTX as a biomaterials pioneer in silicon nitride and guided the company through its early evolution in orthopedic and spinal applications. Mr. Olson has assumed the role of Board Chairman in addition to his ongoing duties as President and CEO. He previously served as CEO of Amedica Corporation, the predecessor to SINTX, and has played a key role in the company’s repositioning into the medical device space. Appointment of Jay Moyes as Lead Independent Director; Mr. Moyes served as CFO of Amedica from 2013 to 2014 and was a Board Member during the Company’s 2014 initial public offering and initial listing on the Nasdaq Capital Market. He also held the position of CFO for Myriad Genetics, CareDx and Sera Prognostics. He brings extensive experience in capital markets, corporate governance, and strategic finance, and has been a board member of multiple private and publicly traded life science companies. Mr. Moyes currently serves on the board of directors of Puma Biotechnology and BioCardia. Appointment of New Directors; Chris Lyons brings more than 35 years of experience in the musculoskeletal and spine markets, with a strong focus on business development, M&A, and strategic growth. He spent 15 years at Smith & Nephew in senior commercial roles before joining Medtronic Spine and Biologics, where he led global business development for over a decade. At Medtronic, he managed acquisitions, investments, and partnerships worldwide. In 2018, he founded Southern Metrics Consulting, advising emerging medtech companies on commercialization and successful exits. Robert (Bob) Mitchellhas over three decades of executive leadership experience in global medical device organizations. At Cook Medical, he led five business units, including interventional radiology and endovascular therapies. He previously served as Vice President of Worldwide Sales at Align Technology (Invisalign) before becoming CEO of Millimed Holdings in Denmark. He also held leadership roles as COO of AngioDynamics and CEO of Nellix (acquired by Endologix). Currently, he Chairs Convi’s HR and Governance Committee, is Chairman of LifeSeal Vascular and Amecath, and an advisor to TVM Capital Healthcare in Dubai. His expertise spans operational leadership, commercialization, and strategic investments. Mark Andersonis a seasoned executive with over 35 years in the medical device industry, primarily with Boston Scientific, a leading medical device company. His experience crossed four divisions Cardiology, Watchman, Endoscopy, and Corporate Contracts. Additionally, he managed the #1 customer for Boston Scientific (HCA Healthcare) for nearly 9 years. Mr. Anderson is recognized for building high-performing teams, expanding global markets, and scaling businesses with a strong commercial and clinical focus. Gregg Honigblumhas been a long-time supporter of SINTX and its predecessor, Amedica. As a former board member and early financial backer, Mr. Honigblum helped raise over $100 million in private funding for the company across multiple rounds. He currently serves as SINTX’s Chief Strategy Officer and has led recent financing efforts, including a successful ATM and PIPE transaction. His background includes investment banking, founding and scaling of medtech companies and extensive experience in capital formation and business strategy.